Skip to main content
. 2016 Jul 27;57(10):2259–2267. doi: 10.1080/10428194.2016.1195501

Table 1.

Risk stratification of patients with MF according to the International Prognostic Scoring System (IPSS),[18] dynamic IPSS (DIPSS),[19] DIPSS plus,[12] and mutation-enhanced IPSS (MIPSS).[20]

Risk category Scale Estimated survival (years)
IPSS No. of risk factors a Median (95% CI)
 Low 0 11.3 (9.8–15.1)
 Intermediate-1 1 7.9 (6.6–9.5)
 Intermediate-2 2 4.0 (3.6–4.9)
 High ≥ 3 2.3 (1.9–2.6)
DIPSS Prognostic score b Median
 Low 0 NR
 Intermediate-1 1 or 2 14.2
 Intermediate-2 3 or 4 4
 High 5 or 6 1.5
DIPSS plus Prognostic score c Median
 Low 0 15.4
 Intermediate-1 1 6.5
 Intermediate-2 2 or 3 2.9
 High 4–6 1.3
MIPSS Prognostic score d Median
 Low 0–0.5 17.6
 Intermediate-1 1–1.5 7.8
 Intermediate-2 2–3.5 4.3
 High ≥ 4 1.6

NR: not reached.

aRisk factors include age > 65 years, constitutional symptoms (defined as weight loss > 10% of baseline value in the year preceding diagnosis and/or unexplained fever or excessive sweats persisting for more than 1 month), hemoglobin <10 g/dL, white blood cell count > 25 × 109/L, and peripheral blood blasts ≥ 1%.

bRisk factors (score) include age >65 years (1), constitutional symptoms (1), hemoglobin < 10 g/dL (2), white blood cell count > 25 × 109/L (1), and peripheral blood blasts ≥ 1% (1).

cScoring is based on DIPSS risk categories (low risk, 0 points; intermediate-1 risk, 1 point; intermediate-2 risk, 2 points; high risk, 3 points) and additional risk factors (unfavorable karyotype, 1 point; platelet count < 100 × 109/L, 1 point; transfusion need, 1 point).

dRisk factors (score) include age >60 years (1.5), constitutional symptoms (0.5), hemoglobin < 100 g/L (0.5), platelet count < 200 × 109/L (1.0), triple-negative mutation status (1.5), JAK2 or MPL mutation (0.5), ASXL1 (0.5), and SRSF2 (0.5).